The introduction of BCR-ABL1 tyrosine kinase inhibitors (TKIs) for treatment of chronic
myelogenous leukemia in chronic phase (CML-CP) has revolutionized therapy, altering the …

In contrast to adult medicine, specific scoring systems predicting the treatment response for
an individual pediatric patient (pt) with chronic myeloid leukemia (CML) have not yet been …

Introduction: The ultimate goal for CML management is risk stratification of the patients to
design the appropriate treatment approach. The Sokal, Euro and EUTOS risk scores were …

Introduction: Real-world treatment and monitoring patterns have not been well documented
among imatinib-treated chronic phase chronic myeloid leukemia (CP-CML) patients. Thus …

The introduction of tyrosine kinase inhibitors has dramatically improved outcomes for many
patients with chronic myeloid leukemia (CML), but some cases are resistant to this treatment …

Pulmonary alveolar proteinosis (PAP) is a rare disease characterized by the accumulation of
eosinophilic periodic acid Schiff-positive material in the intra-alveolar and bronchiolar …

Objective Though the median age at diagnosis is 64 years, few studies focus on elderly (≥
65 years) patients with chronic myeloid leukemia (CML). This study examines healthcare …

We sought to develop and compare prognostic models, based on clinical and/or
morphometric diagnostic data, to enable better prediction of complete cytogenetic response …

Objective: Given the multiple options for treatment of chronic-phase chronic myeloid
leukemia (CML) with tyrosine kinase inhibitors, our objective was to understand treatment …

Introduction: Orally administered tyrosine kinase inhibitors (TKIs) are the cornerstone of
treatment for patients with chronic phase chronic myeloid leukemia (CML). Currently, there is …